Rezolute Announces Positive Interim Data for its Phase 3 upLIFT Study of Ersodetug in Tumor Hyperinsulinism
Rezolute Announces Oral Presentation of Results From its Phase 3 sunRIZE Study of Ersodetug in Patients with Congenital Hyperinsulinism at the Pediatric Endocrine Society Annual Meeting
Rezolute to Present Results from its Phase 3 sunRIZE Study in Congenital Hyperinsulinism at the Pediatric Endocrine Society Annual Meeting
Rezolute Provides Insights from its Phase 3 sunRIZE Study in Congenital Hyperinsulinism and Shares Findings from its Expanded Access Program in Tumor Hyperinsulinism
Blue Jay Gold Corp. Announces Engagement of Oak Hill Financial Inc. for Investor Relations and Retention of Haywood Securities for Market Making Services
QIMC Highlights Technical Advisory Role on First Atlas Matane Natural Hydrogen Project Following Quebec Parliamentary Committee Appearance
